Substance P is an 11-amino acid Neuropeptide of the tachykinin family (defined by proline residues at positions 2 and 4) that functions as both a Neurotransmitters and neuromodulator. It serves as a critical bidirectional signal between the nervous and immune systems, mediating pain transmission, Neurogenic inflammation, immune responses, stress responses, and bone metabolism through binding to neurokinin-1 (NK1) receptors on diverse target cells.
Imagine substance P as a dual-role emergency dispatcher in a building complex. When a fire alarm goes off in one apartment (tissue injury), substance P rushes down from the nerve fiber control room and does two things simultaneously: First, it calls the fire department (immune cells) and tells the building superintendent to open all the fire hydrants (vasodilation) and unlock emergency water reserves (plasma extravasation). This is neurogenic inflammation β the nervous system directly controlling immune and vascular responses without waiting for immune cells to arrive.
But substance P doesn't just work at the injury site. It also runs to the central security office (spinal cord dorsal horn) and amplifies the alarm system itself, turning up the sensitivity of all the smoke detectors (central sensitization). What was once a normal threshold for "fire" (pain) now triggers at much lower levels. The problem is, once substance P has turned up the alarm sensitivity, it's hard to turn it back down β this is why chronic pain persists even after tissues heal.
In chronic stress and chronic pain, substance P gets stuck in "emergency mode," constantly flooding both the local site and the central alarm system, creating a self-perpetuating cycle of inflammation and pain amplification. This is why blocking NK1 receptors (the receivers of substance P's calls) has been explored for both pain and inflammatory conditions.
ΒΆ Release and Receptor Binding
Substance P is synthesized in the cell bodies of small-diameter sensory neurons (C-fibers and AΞ΄-fibers) via the preprotachykinin-A (PPT-A) gene β packaged into dense-core vesicles β transported to both peripheral terminals (in tissues) and central terminals (spinal cord dorsal horn). Release is triggered by:
Upon release, substance P binds preferentially to neurokinin-1 (NK1) receptors, a G-protein coupled receptor (GPCR) linked to Gq/G11 proteins β activates phospholipase A2 (PLA2) β releases arachidonic acid from membrane phospholipids β downstream production of Prostaglandins, Leukotrienes, and inflammatory lipid mediators.
At peripheral terminals, substance P binding to NK1 receptors on:
This creates the classic neurogenic inflammation triad: vasodilation (calor, rubor), plasma extravasation (edema/tumor), and pain (dolor).
At the spinal cord dorsal horn (laminae I and II), substance P:
- Binds NK1 receptors on second-order nociceptive neurons
- Activates protein kinase C (PKC) β phosphorylates NMDA receptor subunits (NR1, NR2B)
- Removes MgΒ²βΊ block from NMDA receptors β allows CaΒ²βΊ influx even at resting membrane potential
- Activates CREB β transcription of pro-nociceptive genes (c-Fos, COX-2, BDNF)
- Triggers microglial activation β release of BDNF, TNF-Ξ±, IL-1Ξ² β further amplification
graph TD
A[Tissue Injury/Stress] --> B[C-fiber Activation]
B --> C[Substance P Release]
C --> D[Peripheral NK1 Binding]
C --> E[Central NK1 Binding]
D --> F[Endothelial Cells]
D --> G[Mast Cells]
D --> H[Macrophages]
F --> I[Plasma Extravasation]
G --> J["Histamine/TNF-Ξ±/IL-6"]
H --> K["IL-1Ξ²/IL-6/TNF-Ξ±"]
I --> L[Neurogenic Inflammation]
J --> L
K --> L
E --> M[NMDA Receptor Phosphorylation]
E --> N[Microglial Activation]
M --> O["CaΒ²βΊ Influx"]
N --> P[BDNF/Cytokine Release]
O --> Q[Central Sensitization]
P --> Q
L --> R[Chronic Pain State]
Q --> R
Substance P directly affects bone remodeling:
- Osteoclasts (bone-resorbing cells) express NK1 receptors β substance P binding β increased RANKL expression β enhanced osteoclast differentiation and activity
- Osteoblasts (bone-forming cells) have lower NK1 receptor density β net effect favors bone resorption over formation
- In CRPS, chronically elevated substance P β osteopenia in affected limbs (Kramer et al., 2014)
Chronic stress β elevated CRH and Cortisol β upregulation of PPT-A gene expression in dorsal root ganglia β increased substance P synthesis and release β explains stress-pain and stress-inflammation links in cPNI.
Substance P is central to understanding chronic pain, particularly:
- Neuropathic pain β damaged nerves release excessive substance P without tissue injury
- Fibromyalgia β elevated cerebrospinal fluid (CSF) substance P levels (mean 3.1 ng/mL vs 1.8 ng/mL in controls)
- CRPS (Complex Regional Pain Syndrome) β high local substance P drives neurogenic inflammation, osteopenia, and abnormal hair/nail growth via keratinocyte stimulation (Birklein & Schmelz, 2008)
- Migraine β trigeminal release of substance P contributes to meningeal inflammation and pain
Substance P represents a key example of neurogenic control of immunity (Metamodel 3: Neuro-Endocrine-Immune Integration):
NK1 Receptor Antagonists (e.g., aprepitant, originally for chemotherapy-induced nausea):
- Tested in chronic pain trials with mixed results
- More effective when targeting both peripheral and central NK1 receptors
- Clinical threshold for intervention: CSF substance P >2.5 ng/mL in chronic pain states
cPNI Interventions that reduce substance P:
- Vagus nerve stimulation β cholinergic anti-inflammatory pathway reduces substance P release
- Cold exposure β transient TRPV1 desensitization β reduced substance P depletion from nerve terminals
- Capsaicin (topical) β initial TRPV1 activation and substance P depletion β subsequent desensitization and pain relief
- Curcumin and Resveratrol β downregulate PPT-A gene expression and NK1 receptor density
- Stress management β reduces CRH-driven substance P upregulation
ΒΆ Selfish Brain and Evolutionary Mismatch
In ancestral environments, acute substance P release during injury was adaptive (rapid immune activation and pain signaling for protective withdrawal). In modern chronic stress environments, persistent substance P activation represents an evolutionary mismatch β a system designed for acute threats now chronically activated by psychological stressors, creating maladaptive pain amplification and immune dysregulation.
- Structure: 11 amino acids (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met) with defining proline residues at positions 2 and 4
- Primary receptor: Neurokinin-1 (NK1), with lower affinity for NK2 and NK3
- Release sites: Peripheral nerve terminals (neurogenic inflammation) and central terminals (spinal cord dorsal horn, pain transmission)
- Half-life: 1-2 minutes in plasma (rapidly degraded by neutral endopeptidase/neprilysin)
- CSF levels: Normal <2.0 ng/mL; fibromyalgia 2.5-4.0 ng/mL; chronic pain >2.5 ng/mL
- Neurogenic inflammation triad: Vasodilation, plasma extravasation, immune cell activation
- Central sensitization role: Phosphorylates NMDA receptors β removes MgΒ²βΊ block β chronic pain amplification
- Stress link: CRH and cortisol upregulate PPT-A gene expression in sensory neurons
- Bone effects: Activates osteoclasts > osteoblasts β net bone resorption in CRPS
- Immune activation: Triggers mast cell degranulation, macrophage cytokine production, neutrophil chemotaxis
- Clinical interventions: NK1 antagonists, capsaicin depletion, vagal stimulation, polyphenols (curcumin, resveratrol)
- C tactile fibres β C-fibers are the primary source of substance P release in skin and peripheral tissues
- A-delta fibres β AΞ΄-fibers also release substance P, contributing to first and second pain transmission
- TRPV1 β capsaicin activation of TRPV1 channels triggers massive substance P release and subsequent depletion
- Neurogenic inflammation β substance P is the primary mediator of neurogenic inflammation, acting directly on blood vessels and immune cells
- Central sensitization β substance P phosphorylates NMDA receptors in dorsal horn, creating chronic pain amplification
- Mast Cell Degranulation β NK1 receptor activation on mast cells triggers degranulation and histamine release
- Mast cells β express high-density NK1 receptors and are primary targets for substance P in neurogenic inflammation
- CGRP β co-released with substance P from sensory nerve terminals; synergistic effects in neurogenic inflammation and CRPS
- Chronic pain β elevated substance P in CSF and tissues contributes to chronic pain states through peripheral and central mechanisms
- Fibromyalgia β CSF substance P levels 2-3x higher than controls, correlating with pain severity
- CRPS β excessive substance P drives inflammation, bone loss, and abnormal tissue growth in affected limbs
- Stress β chronic stress upregulates PPT-A gene via CRH and cortisol, increasing substance P synthesis
- CRH β directly stimulates substance P synthesis in dorsal root ganglia neurons
- Cortisol β biphasic effect: acute suppresses substance P release, chronic upregulates PPT-A gene expression
- Leukotrienes β substance P activates 5-LOX pathway via PLA2, producing pro-inflammatory leukotrienes
- Prostaglandins β substance P activates COX pathway via PLA2, producing PGE2 and other prostaglandins
- IL-6 β released by macrophages and mast cells upon substance P stimulation; amplifies inflammatory response
- TNF-Ξ± β released by mast cells and macrophages in response to substance P; contributes to peripheral and central sensitization
- NMDA receptor β substance P phosphorylates NMDA receptor subunits, removing MgΒ²βΊ block and enabling central sensitization
- BDNF β substance P induces BDNF expression in spinal cord via CREB activation; BDNF further amplifies pain signaling
- Microglia β activated by substance P in spinal cord; release cytokines and BDNF that enhance nociceptive transmission
- Osteoclast β substance P activates osteoclasts via NK1 receptors, promoting bone resorption
- Osteoblasts β lower NK1 receptor density compared to osteoclasts; net effect of substance P is bone loss
- osteopenia β chronic substance P elevation in CRPS causes osteopenia through enhanced osteoclast activity
- Vagus nerve β vagal stimulation reduces substance P release via cholinergic anti-inflammatory pathway
- Capsaicin β TRPV1 agonist that depletes substance P from nerve terminals; used therapeutically in chronic pain
- Curcumin β downregulates PPT-A gene expression and reduces NK1 receptor density
- Resveratrol β inhibits substance P synthesis and NK1 receptor signaling
- Migraine β trigeminal nerve release of substance P contributes to meningeal inflammation and migraine pain
- IBD β substance P levels elevated in inflamed gut tissue; contributes to intestinal inflammation
- Rheumatoid arthritis β synovial fluid substance P correlates with joint inflammation and pain severity
- Psoriasis β cutaneous substance P contributes to keratinocyte proliferation and inflammatory plaques
- Module 4 β Substance P as neuropeptide mediator
- Module 5 β Role in nociception and neurogenic inflammation; injection therapy targeting substance P at injury site and corresponding spinal segment